Our approach
Leaning on the power of AI, we shift the drug discovery process into patient-based cellular models.
Our versatile deeptech drug discovery platform exploits outstanding expertise in complex human (patient derived) and animal cellular disease modeling, assay automation and validation, together with key assets in AI-powered phenotypic profiling and data integration to reveal novel therapeutic opportunities.
We functionalize patient-based disease models for Target and Drug Discovery and develop screening solutions using complex cellular systems
AI-assisted high-content analysis renders complex disease models applicable for large-scale phenotypic target and drug discovery.
PREDICTIVE.
Complex patient-based models. AI allows us to tackle intrinsic batch-to batch variability and to establish authentic and predictive disease models.
SCALABLE.
“Scalability thinking” from the start. Our Image & Data mining team develops tailored algorithms to deal with large amounts of biological data generated in house from automated assays.
INTERPRETABLE.
Tailored algorithms. Our team develops tailored algorithms to extract information from large datasets generated in house and enrich / corroborate with external data.
Driven by AI
The power of AI is key for all our activities. We use Profiling and Deep Learning methodologies to analyse thousands of subtle morphometric read-outs, allowing for the compensation of inherent variability of complex cellular and patient-based disease models. AI also enables fast interpretation of our generated imaging datasets, deciphering human disease biology.
Our focus on phenotypic profiling of complex cellular and patient-based assays sets us apart in the field.
